Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.76 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.76 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.76 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.76 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.76 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.76 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 7/20 | 0.53 |
| ▸ | CACNG8 | Q8WXS5 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769722 | 0.86 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL762964 | 0.83 | GRIN2D (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL640124 | 0.83 | GRIA1 (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27474539 | 0.82 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19068666 | 0.77 | ALDH1A1 (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1115539 | 0.73 | GRIA1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1827312 | 0.73 | ALDH1A1 (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1829719 | 0.73 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1439986 | 0.73 | ALDH1A1 (0.63) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19644507 | 0.73 | GRIA1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194308-A1 | NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | NOVASAID AB (SE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194308-A1 | NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | NOVASAID AB (SE) | 2016-07-07 | — | — | US | disclosed |
| US-20160122330-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | NOVASAID AB (SE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122330-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | NOVASAID AB (SE) | 2016-05-05 | — | — | US | disclosed |
| EP-3010913-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | Novasaid AB (SE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014204371-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | CADILA PHARMACEUTICALS LTD. (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014204370-A1 | NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | CADILA PHARMACEUTICALS LTD. (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014204371-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | CADILA PHARMACEUTICALS LTD. (IN) | 2014-12-24 | — | — | WO | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-1397434-B1 | BASIC MONOAZO COMPOUNDS | CLARIANT FINANCE BVI LTD (VG) | 2012-12-26 | — | — | EP | disclosed |
| EP-2495244-A1 | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors | NovaSaid AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194308-A1 | NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | FAP, APC, PTGES | GRIN2D 2673/4885GRIN3B 3180/4885GRIN1 1596/4885 |
| US-20160122330-A1 | PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS | FAP, APC, PPM1D | GRIN2D 3913/4885GRIN3B 3901/4885GRIN1 1778/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | GRIN2D 3253/4885GRIN3B 3432/4885GRIN1 3931/4885 |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | GRIN2D 676/4885GRIN3B 324/4885GRIN1 344/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | GRIN2D 685/4885GRIN3B 316/4885GRIN1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.